Smad3 signalling affects high glucose-induced podocyte injury via regulation of the cytoskeletal protein transgelin.

AIM

The aim of the present study was to characterize the role of Smad3 signalling on high glucose-induced podocyte injury.

METHODS

Synchronized conditionally immortalized mouse podocyte cell line (MPC5) cells were treated with either D-glucose alone or D-glucose plus the Smad3 inhibitor SIS3. The distribution of F-actin and transgelin in a high glucose-induced model of podocyte injury were examined by immunofluorescence. Levels of transgelin and Smad3 signalling proteins in MPC5 cells were determined by Western blot.

RESULTS

A disordered distribution of F-actin, as well as co-localization of F-actin and transgelin, was observed in podocytes exposed to high glucose. Increased levels of transgelin were first observed 10 minutes after treatment with glucose, suggesting that this protein is sensitive to hyperglycaemic injury. Levels of phosphorylated Smad3 and cleaved caspase 3 increased significantly with glucose stimulation. Moreover, expression of the downstream protein c-Myc, but not JAK1/STAT3, was induced in conditions of high glucose. The Smad3-specific inhibitor SIS3 prevented the effects of high glucose on Smad3 phosphorylation, expression of transgelin and c-Myc, caspase 3 cleavage and cytoskeletal organization. Expression of the tumour suppressor protein p15 increased after podocyte injury but was unaffected by Smad3 inhibition, suggesting that Smad3 regulation of high glucose-induced podocyte injury occurs through a p15 -independent mechanism.

CONCLUSION

Smad3 signalling plays a critical role in the modulation of hyperglycaemic injury. Targeted inhibition of the Smad3 pathway may offer a novel route for treatment of podocyte damage, especially in cases of diabetic nephropathy.